Moderna, the first to start human testing of a COVID vaccine, began a phase 1 safety study of its candidate vaccine in a small group of healthy adults on March 16, 2020.

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic began—proof that health authorities had planned the pandemic in advance.

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it.

In a turbulent market environment, Moderna Inc (BMV:MRNA). shares have touched a 52-week low, sinking to $30.7, with concerning financial metrics showing negative EBITDA of $2.36 billion and gross ...

In 2023, Moderna initiated a study on a “pandemic influenza vaccine” to protect against H5 and H7 avian influenza viruses. In July, the company received $176 million from HHS toward its ...

There have been 67 confirmed human bird flu cases in the U.S. since April 2024. Moderna has been awarded approximately $590 million from the federal government to help speed up the development of ...

The study included vaccine candidates against H5 and ... impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly ...

Moderna's stock roared higher on the back of news about potential AI mRNA vaccines. The company also secured a supply contract in Europe. Shares of Moderna are down 90%, and the company has a huge ...

Massachusetts-based Moderna will likely be the first to manufacture a bird flu vaccine, backed by hundreds of millions in government funding. The biopharmaceutical giant is developing the vaccine ...

Moderna MRNA-0.81%decrease ... Human Services Department to accelerate the development of its bird influenza vaccine as concerns grow about a bird flu pandemic in humans. The financial package ...

For more information about Moderna ... and potential for up to 17 participating countries to order COVID-19 vaccines from Moderna over a four-year period; and healthcare provider preferences ...